Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG in Pediatric Toxic Shock Syndrome
NCT02899702Phase 4Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2020
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of intravenous immunoglobulin G in toxic shock syndrome (TSS), sponsored by Hospices Civils de Lyon. Planned start Sep 2020; status: withdrawn.
02
Drugs
intravenous immunoglobulin G
03
Conditions
toxic shock syndrome (TSS)
Beyond the preview
Go deeper on NCT02899702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899702.